SUMATRIPTAN HEMISULPHATE
Medication Overuse Headache
IRCCS San Raffaele RomaSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Medication Overuse Headache cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eptinezumab Beijing Tiantan Hospital | Phase 4 | BBB |
Frovatriptan University of Calgary | Phase 2 | B |
Yangxue Qingnao Granules Beijing Tiantan Hospital | D | |
Topamax Ataturk University | N/A | D |
Treximet® IRCCS San Raffaele Roma | D |
View all 9 →
Same molecule, other indications
SUMATRIPTAN HEMISULPHATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →